statistiche ricercatore

Continente	#
NA - Nord America	414
EU - Europa	336
AS - Asia	311
SA - Sud America	62
AF - Africa	33
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	1
Totale	1.159

Nazione	#
US - Stati Uniti d'America	403
IT - Italia	113
SG - Singapore	107
CN - Cina	65
SE - Svezia	54
BR - Brasile	51
DE - Germania	41
HK - Hong Kong	37
GB - Regno Unito	34
VN - Vietnam	34
IN - India	29
FR - Francia	24
FI - Finlandia	16
CI - Costa d'Avorio	15
BG - Bulgaria	14
JP - Giappone	13
ID - Indonesia	7
NL - Olanda	7
RU - Federazione Russa	7
PT - Portogallo	6
SN - Senegal	6
CA - Canada	5
ES - Italia	5
NG - Nigeria	5
TR - Turchia	5
MX - Messico	4
PL - Polonia	4
ZA - Sudafrica	4
AR - Argentina	3
UZ - Uzbekistan	3
VE - Venezuela	3
BD - Bangladesh	2
CH - Svizzera	2
CO - Colombia	2
IQ - Iraq	2
MA - Marocco	2
TT - Trinidad e Tobago	2
XK - ???statistics.table.value.countryCode.XK???	2
AE - Emirati Arabi Uniti	1
AT - Austria	1
AU - Australia	1
BE - Belgio	1
BN - Brunei Darussalam	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EC - Ecuador	1
EE - Estonia	1
HR - Croazia	1
IE - Irlanda	1
JO - Giordania	1
LV - Lettonia	1
MO - Macao, regione amministrativa speciale della Cina	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
PY - Paraguay	1
SI - Slovenia	1
TW - Taiwan	1
UA - Ucraina	1
Totale	1.159

Nome	#
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy	174
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases	159
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons	157
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact	134
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy	133
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES	125
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients	119
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis	109
Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort.	65
Totale	1.175

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	14	0	0	0	0	0	0	0	0	0	0	2	12
2021/2022	142	6	5	21	36	17	13	3	6	6	3	8	18
2022/2023	131	17	27	12	5	11	10	8	1	28	0	12	0
2023/2024	114	0	5	10	2	10	16	20	14	1	0	17	19
2024/2025	385	7	13	20	35	24	45	32	14	28	50	49	68
2025/2026	370	36	39	43	25	46	22	71	13	27	41	7	0
Totale													1.175

CINECA IRIS Institutional Research Information System